RAPP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
-100.0%
20.0M
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
20.0M
0
0
Operating Expenses
44.1M
-27.5%
60.8M
+37.5%
44.2M
+14.8%
38.5M
+28.4%
30.0M
R&D
34.3M
-33.3%
51.4M
+57.2%
32.7M
+8.1%
30.3M
+35.8%
22.3M
SG&A
9.8M
+4.0%
9.4M
-18.3%
11.5M
+39.4%
8.3M
+7.1%
7.7M
Operating Income
-44086000
+27.5%
-60806000
-151.1%
-24215000
+37.1%
-38509000
-28.4%
-29986000
EBITDA
-43888000
+27.6%
-60594000
-152.6%
-23988000
+37.3%
-38244000
-28.6%
-29730000
Net Income
-40235000
+28.9%
-56615000
-185.1%
-19857000
+41.2%
-33763000
-25.4%
-26925000
EPS (Basic)
$-0.84
+29.4%
$-1.19
-183.3%
$-0.42
+41.7%
$-0.72
-1.4%
$-0.71
EPS (Diluted)
$-0.84
+29.4%
$-1.19
-183.3%
$-0.42
+41.7%
$-0.72
-1.4%
$-0.71
Shares (Diluted)
47.8M
+0.6%
47.5M
+0.5%
47.2M
+0.3%
47.1M
+24.2%
37.9M
Rapport Therapeutics (RAPP) — Financials